NCT02396134 - Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2015

Primary Completion Date

March 4, 2018

Study Completion Date

September 19, 2024

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Hodgkin LymphomaAdult Non-Hodgkin LymphomaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCytomegaloviral InfectionHematopoietic and Lymphoid Cell NeoplasmHLA-A*0201 Positive Cells PresentMyelodysplastic SyndromeAdult Lymphoblastic LymphomaChronic Lymphocytic LeukemiaMyelofibrosisMyeloproliferative Neoplasm

Interventions

BIOLOGICAL

CMVpp65-A*0201 peptide vaccine

Given SC

OTHER

Placebo

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (5)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

91010

City of Hope Medical Center, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER